January 10, 2017
Novo Nordisk A/S – Share repurchase programme
On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
January 10, 2017
Cumberland Pharmaceuticals to distribute Clinigen’s cancer treatment aid Totect in U.S.
Clinigen Group has made a deal with Cumberland Pharmaceuticals to market another product in the US, this time an oncology drug Totect (dexrazoxane hydrochloride).
January 10, 2017
IT provider for healthcare market Instem names new COO
An IT provider for healthcare market Instem, has appointed MaryBeth Thompson as Chief Operating Officer of the Group. Thompson has not been appointed to the company’s main Board, and she will report to Phil Reason, CEO.
January 10, 2017
Oxular Limited, a retinal therapeutics company, has promoted David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a Director.
January 9, 2017
Allergan, Assembly in microbiome gastrointestinal licensing deal
Allergan has made a deal to get Assembly Biosciences’s microbiome gastrointestinal (GI) development programs which will enable Allergane to use more compounds in researching stomach problems.
January 9, 2017
Allergan expands its neurological diseases arm, buys Lysosomal Therapeutics
Allergan has purchased an exclusive option right to acquire Lysosomal Therapeutics (LTI), the company focused on innovative small-molecule research and…
January 9, 2017
Roche gets FDA’s priority review for Tecentriq to treat different type of bladder cancer
Roche said on Monday that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) for metastatic urothelial carcinoma (mUC).
January 9, 2017
Innate Pharma cashes $15million milestone payment from Bristol-Myers for lirilumab-Opdivo testing
Bristol-Myers Squibb (BMS) has reached a payment milestone in connection with the licensing deal with Innate Pharma for lirilumab in combination with Opdivo. BMS has paied Innate $15 million.
January 9, 2017
Takeda notifies 4.48% shareholding in TiGenix
On January 4, 2017, TiGenix received a transparency notification from related companies Takeda Pharmaceutical Company Limited/Takeda Pharmaceuticals International AG, following…
January 9, 2017
Argenx starts Phase II study of myasthenia gravis drug
Argenx, a European biopharmaceutical company focused on drugs for the treatment of cancer and autoimmune diseases, has initiated a Phase…